GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (LTS:0K95) » Definitions » Price-to-Tangible-Book

Northwest Biotherapeutics (LTS:0K95) Price-to-Tangible-Book : (As of Jun. 23, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Northwest Biotherapeutics Price-to-Tangible-Book?

As of today (2024-06-23), Northwest Biotherapeutics's share price is £2.40. Northwest Biotherapeutics's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was £-0.05. Hence, Northwest Biotherapeutics's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Northwest Biotherapeutics's Price-to-Tangible-Book or its related term are showing as below:

LTS:0K95's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.63
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Northwest Biotherapeutics's share price is £2.40. Northwest Biotherapeutics's Book Value per Sharefor the quarter that ended in Mar. 2024 was £-0.05. Hence, Northwest Biotherapeutics's P/B Ratio of today is .


Northwest Biotherapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Northwest Biotherapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics Price-to-Tangible-Book Chart

Northwest Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Northwest Biotherapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Northwest Biotherapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Northwest Biotherapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Northwest Biotherapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's Price-to-Tangible-Book falls into.



Northwest Biotherapeutics Price-to-Tangible-Book Calculation

Northwest Biotherapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=2.40/-0.05
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Northwest Biotherapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Northwest Biotherapeutics (LTS:0K95) Business Description

Traded in Other Exchanges
Address
4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

Northwest Biotherapeutics (LTS:0K95) Headlines

No Headlines